Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Qiagen N.V. Common Shares (NY:QGEN)

48.34 -0.30 (-0.62%)
Official Closing Price Updated: 5:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 6 7 Next >
QIAGEN Reaches Milestone With 100 Million QuantiFERON Tests Used to Detect TB
From QIAGEN N.V.
Via Business Wire
QIAGEN Announces 20-F Annual Report Filing for 2021 Results
From QIAGEN N.V.
Via Business Wire
Death Cross Looms Over Qiagen Investors
If history is any guide, there may be trouble ahead for shares of Qiagen (NYSE:QGEN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Qiagen Q4 Earnings Beat Expectations On High Demand For COVID-19 Tests, Issues FY22 Guidance
Qiagen N.V. (NYSE: QGEN)  
Via Benzinga
Qiagen: Q4 Earnings Insights
Qiagen (NYSE:QGEN) reported its Q4 earnings results on Tuesday, February 8, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Qiagen beat estimated earnings by... 
Via Benzinga
QIAGEN beats outlook for fourth quarter and full-year 2021, delivers 22% CER full-year sales growth from non-COVID products
From QIAGEN N.V.
Via Business Wire
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For February 8, 2022
Companies Reporting Before The Bell • Pfizer (NYSE:PFE) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion. 
Via Benzinga
Qiagen's Earnings: A Preview
Qiagen (NYSE:QGEN) is set to give its latest quarterly earnings report on Tuesday, 2022-02-08. Here's what investors need to know before the announcement. Analysts estimate that Qiagen will likely... 
Via Benzinga
QIAGEN’s New Generation of QuantiFERON TB Test Gains Chinese Approval and Renewed WHO Recommendation
From QIAGEN N.V.
Via Business Wire
QIAGEN’s Commitment to LGBTQ+ and Gender Equality Recognized by Human Rights Campaign and Bloomberg Indexes
From QIAGEN N.V.
Via Business Wire
QIAGEN Completes U.S. Federal Contract to Equip Local Public Health Authorities with QIAcuity Digital PCR System for COVID-19 Surveillance
From QIAGEN N.V.
Via Business Wire
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... 
Via Benzinga
QIAGEN N.V. to release results for Q4 2021 and Full-Year of 2021
From QIAGEN N.V.
Via Business Wire
QIAGEN Launches QIAwave Portfolio of Environmentally Friendly Products
From QIAGEN N.V.
Via Business Wire
What Does Qiagen's Debt Look Like?
Over the past three months, shares of Qiagen (NYSE:QGEN) moved lower by 5.06%. Before we understand the importance of debt, let us look at how much debt Qiagen has. Qiagen... 
Via Benzinga
QIAGEN expands QIAstat-Dx syndromic testing menu and announces launch plans for new QIAstat-Dx Rise higher-throughput version
From QIAGEN N.V.
Via Business Wire
QIAGEN Strengthens Growing Portfolio of Applications for Its Digital PCR Platform QIAcuity With New Collaborations
From QIAGEN N.V.
Via Business Wire
QIAGEN Expands QuantiFERON Portfolio in the Fight Against TB
From QIAGEN N.V.
Via Business Wire
Free COVID Tests: What Stocks Will Benefit?
The government hasn’t announced yet what company or companies it will be buying from, but there are several businesses involved in producing these kits. 
Via Talk Markets
The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug... 
Via Benzinga
QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
From QIAGEN N.V.
Via Business Wire
QIAGEN Launches CE-marked Version of QuantiFERON® SARS-CoV-2 to Assess T-cell Response to COVID-19
From QIAGEN N.V.
Via Business Wire
QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of QuantiFERON®-TB Gold Plus assay on LIAISON® XS
From QIAGEN N.V.
Via Business Wire
Qiagen Says Its COVID-19 PCR Tests Can Detect The New South African Variant
Qiagen N.V. (NYSE:QGEN) announced that its polymerase c... 
Via Benzinga
Rising Test Accuracy Standards Needed as On-Site Demand for Covid-19 Testing Increases
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 9, 2021 – USA News Group – After the launch of US President Joe Biden’s pushing of mandatory vaccination/testing in the... 
Via FinancialNewsMedia
QIAGEN Commits to Reduce Carbon Emissions by Setting Science-Based Target to Reach Net Zero by 2050
From QIAGEN N.V.
Via Business Wire
Qiagen, Becton Dickinson Settle Patent Infringement Lawsuit For $53M
Qiagen N.V. (NYSE: QGEN) settled with Becton Dickinson & Co (NYSE: BDX) a patent infringement lawsuit related to Qiagen's NeuMoDx 96 and NeuMoDx... 
Via Benzinga
Topics Intellectual Property Lawsuit
QIAGEN and BD Settle Patent Infringement Lawsuit
From QIAGEN N.V.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.